Tag Archive for: MED3000

Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into an exclusive licensing agreement with Cooper Consumer Health  (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise the […]

Read more

Futura Medical Full Year Results for the year ended 31 December 2021

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce its audited results for the year ended 31 December 2021. Read more…

Read more

Futura Announces Collaboration with Menarini Korea to Commercialise MED3000 in South Korea

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into a licensing agreement with A. Menarini Korea Limited (“Menarini Korea”), a wholly owned subsidiary of Menarini Group, for […]

Read more

Futura provides US regulatory and commercial update for MED3000

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, is pleased to provide an update on good progress with its regulatory and commercial activities for MED3000. MED3000 is the Company’s breakthrough, topical gel formulation for treatment of erectile dysfunction (“ED”).  It has the potential […]

Read more